Keywords: ASBMR 2012 meeting, Amgen, Merck & Co, Eli Lilly, UnigGene, Prolia, Teriparatide, Odanacatib, GlobalData

ASBMR 2012: Anabolics and post-marketing studies

Article | 25 October 2012

Print This

This year’s American Society for Bone and Mineral Research (ASBMR) conference, held in Minneapolis, Minnesota, October 10–15, had ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in